Ikarian Capital’s Sutro Biopharma STRO Stock Holding History

Ikarian Capital’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13,458	Closed	-$2.54M	–	232
2021 Q3	$2.54M	Sell	13,458 -78	-0.6%	-$14.8K	0.18%	113
2021 Q2	$2.52M	Hold	13,536	–	–	0.2%	118
2021 Q1	$3.08M	Sell	13,536 -48,000	-78%	-$11.4M	0.1%	170
2020 Q4	$13.4M	Buy	61,536 +12,736	+26%	+$2.11M	0.59%	40
2020 Q3	$4.9M	Buy	+48,800	New	+$4.61M	0.35%	70

Other funds holding STRO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Ikarian Capital's STRO Position: Q4 2021 in Review

Ikarian Capital sold out of Sutro Biopharma (STRO) in Q4 2021, closing a stake of 13,458 shares — an estimated $2.54M sold.

Ikarian Capital first reported a position in STRO in Q3 2020 and held it in 5 quarters. The position peaked at $13.4M in Q4 2020. 117 funds tracked by Wall St. Rank hold STRO as of Q4 2021.

Ikarian Capital reported no remaining Sutro Biopharma position as of Q4 2021 after selling out during the quarter.
Ikarian Capital sold 13,458 Sutro Biopharma shares in Q4 2021, an estimated $2.54M.
Ikarian Capital first reported a position in Sutro Biopharma in Q3 2020 and held it in 5 quarters.
Ikarian Capital's Sutro Biopharma position peaked at $13.4M in Q4 2020.
117 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2021.

Based on Ikarian Capital's 13F filing for Q4 2021, filed 14 Feb 2022.